Preclinical Evaluation of [18F]LCATD as a PET Tracer to Study Drug-Drug Interactions Caused by Inhibition of Hepatic Transporters

Testa, AndreaDall'Angelo, SergioMingarelli, MarcoAugello, AndreaSchweiger, LutzWelch, AndrewElmore, Charles SDawson, DanaSharma, PradeepZanda, Matteo2018-08-082018-08-082018-07-30Testa, A, Dall'Angelo, S, Mingarelli, M, Augello, A, Schweiger, L, Welch, A, Elmore, C S, Dawson, D, Sharma, P & Zanda, M 2018, 'Preclinical Evaluation of [ 18 F]LCATD as a PET Tracer to Study Drug-Drug Interactions Caused by Inhibition of Hepatic Transporters', Contrast Media & Molecular Imaging, vol. 2018, 3064751. https://doi.org/10.1155/2018/30647511555-4317PubMedCentral: PMC6091370ORCID: /0000-0003-2815-4469/work/160846715ORCID: /0000-0001-9377-0474/work/176747531http://hdl.handle.net/2164/10875Acknowledgements: A.T. gratefully acknowledges SINAPSE (www.sinapse.ac.uk) and AstraZeneca (UK) for co-funding a studentship. P.S. and C.S.E. are employees of AstraZeneca Ltd., UK. This project has also received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 675417.103129054engR Medicine (General)European Commission675417R1Preclinical Evaluation of [18F]LCATD as a PET Tracer to Study Drug-Drug Interactions Caused by Inhibition of Hepatic TransportersJournal article10.1155/2018/3064751